To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid‐1 (TRPV1), would silence TRPV1‐expressing bladder afferents at an early stage… Click to show full abstract
To investigate if intravesical administration during spinal shock of resiniferatoxin (RTX), an ultrapotent desensitizing agonist of transient receptor potential vanilloid‐1 (TRPV1), would silence TRPV1‐expressing bladder afferents at an early stage of disease progression and modulate neurogenic detrusor overactivity (NDO) emergence.
               
Click one of the above tabs to view related content.